Company / R&D per Share
Outlook Therapeutics, Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.75
FY2025
5-year range
$0.83 / $2.05
FY2021-FY2025
Trend
+110.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D per Share has fluctuated over the past 6 years, ranging from $0.83 in FY2020 to $4.12 in FY2016.
Based on SEC 10-K filings.
1.75 in FY2025 with a 5-year CAGR of +16.0%.
Declined from $2.05 to $1.75 over the past 6 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +16.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, r&d per share increased 110.0% year-over-year.
- Peak r&d per share was recorded in FY2016.
- Lowest r&d per share in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -13.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.75 | +110.0% |
| FY2020 | $0.83 | -59.4% |
| FY2019 | $2.05 | +114.7% |
| FY2018 | $0.95 | -33.5% |
| FY2017 | $1.44 | -65.1% |
| FY2016 | $4.12 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026